Dyslipidemia and lower extremity arterial disease.

Dyslipidemia is an established risk factor for cardiovascular diseases. We aimed to review its role in the pathogenesis of lower extremity arterial disease (LEAD), as well as the effect of lipid-lowering treatment on the progression of LEAD. PubMed/MedLine, EMBASE and Scopus were searched between January 1990 and January 2024 for articles investigating the role of dyslipidemias and hyperlipidemias in the pathogenesis of LEAD. A separate search focused on the effects of lipid-lowering therapy on patients with LEAD. There is evidence that dyslipidemias play a major role in the development of LEAD. All patients with LEAD should receive intensive lipid-lowering therapy for the reduction not only of claudication symptoms and amputation rates, but also of myocardial infarction and cardiovascular event rates. Vascular specialists should keep in mind the pivotal role of dyslipidemia in the pathogenesis and progression of LEAD.

Citation

Kosmas I Paraskevas, Pavel Poredos, Agata Stanek, Ales Blinc, Arkadiusz Jawien, Pier Luigi Antignani, Armando Mansilha, Dimitri P Mikhailidis. Dyslipidemia and lower extremity arterial disease. International angiology : a journal of the International Union of Angiology. 2024 Aug;43(4):450-457

Mesh Tags

Substances

PMID: 39302145

search → result